Background: Fluoropyrimidine and platinum were established as the backbone for adjuvant treatment of early-stage colon cancer in 2004. However, the cumulative neurotoxicity associated with oxaliplatin, persisting at times for long periods of time after the end of adjuvant therapy. There were several efforts underway to assess if a shorter duration of ad…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.